The 'Nuclear War' in Tumor Early Detection: Abbott’s $21 Billion Acquisition and Roche’s Strategic Bet Within 24 Hours

Exact Sciences’ Cologuard has become the industry benchmark because it successfully navigated the most difficult hurdle: in the same year it received FDA approval (2014), the U.S. Centers for Medicare & Medicaid Services (CMS) approved coverage—and Medicare began reimbursing it. In 2024, a modeling study by Exact Sciences estimated that over the past decade, more than 16 million people in the U.S. have completed colorectal cancer screening using Cologuard, saving Medicare approximately $22 billion. Once reimbursement pathways for early detection tests become clear and predictable, global giants no longer see this space as an uncertain ‘innovation track,’ but rather as a proven, scalable, and profitable mature commercial market. Second: A paradigm shift in technology—from ‘single-point’ to ‘system-level’ solutions. The technological upside of single-gene or single-methylation biomarkers has nearly reached its ceiling. Today’s competition is about integrated system capabilities—‘multi-omics + AI.’ Abbott and Roche’s recent moves likely reflect their recognition that traditional PCR-based assays or single-biomarker approaches can no longer build sustainable competitive moats. Roche’s acquisition of Freenome hinges precisely on its ‘multi-omics + AI’ platform—a capability increasingly becoming the new standard for international M&A in diagnostics. Third: Giants need growth. From a financial reporting perspective, multinational medtech firms currently face slowing growth from mature products; tumor early detection remains one of the few incremental markets with ‘billion-dollar’ potential. Over the next three years, the window of opportunity will rapidly close for small early-detection startups with only a single pipeline. There are only two possible outcomes: either they collapse under the weight of prohibitively expensive prospective clinical trials—or they get acquired by a major player, becoming a piece of its broader ecosystem. Beyond this, the boundary between pharmaceuticals and IVDs is blurring: pharma companies need early detection tools to identify patients at earlier disease stages and expand their treatable populations; IVD companies need real-world clinical data from pharma partners to refine and validate their tests. In the future, ‘early detection + companion diagnostics + therapy’ may evolve into an integrated, bundled solution. 03. The ‘Peril and Promise’ of China’s Cancer Early Detection Sector: There Should Be No Second ‘NovoHealth’ While global giants across the Pacific scramble to carve up the future landscape through capital maneuvers, China’s domestic early-detection industry is enduring a bone-chilling ‘late-spring cold snap.’ Over the past two years, as NovoHealth—the sector’s leading company—became embroiled in operational controversies, the entire early-detection field was thrust under the harshest spotlight for scrutiny. A telling detail: that certificate once hailed as a milestone—the ‘first-ever regulatory approval for colorectal cancer early detection in China’—has recently been quietly moved to the ‘historical data’ category in the NMPA database—a signal typically indicating that the original registration certificate has expired and renewal remains pending. When the tide recedes, those swimming naked are exposed—but true value rises to the surface. Technologically, China’s early-detection capabilities have already gained global recognition. On November 18, TreeGen (Tongshu Gene) announced licensing its MRD (Minimal Residual Disease) monitoring platform to NASDAQ-listed BioNexus, with initial deployment in Southeast Asia—and ambitions targeting FDA and EMA approvals. This sends a strong signal: Chinese IVD enterprises are upgrading from ‘product export’ to ‘technology standard export.’

Worldview · New Horizons: Investment Incentives for Biotechnology and Bio-Based Industries in Malaysia

For newly established biotechnology enterprises or expansion projects, Malaysia implements a tiered tax exemption policy. For example, BioNexus-certified enterprises qualify for full statutory income tax exemption for the first 10 years, followed by a reduced 20% tax rate for the subsequent 10 years. The duration of this exemption is dynamically adjusted based on investment scale, technological complexity, and industrial spillover effects—for instance, Biocon’s insulin manufacturing facility in Johor achieved a 10-year tax exemption by introducing nasal insulin technology, and earned an additional five years of tax incentives due to its export contribution. According to MIDA data, qualified green technology assets are eligible for capital expenditure subsidies of up to 70% during 2024–2026—creating a compound incentive effect combining ‘tax exemption + subsidy.’ 2. Green Investment Tax Allowance (GITA): A Targeted Capital Subsidy for Green Investments Under the ‘Green Technology Tax Incentive Guidelines,’ enterprises may claim a 70% GITA subsidy on qualified capital expenditures incurred for in-house green technology assets during 2024–2026. This policy directly stimulates investment in renewable energy equipment, energy-efficient production systems, and carbon capture technologies. For example, Topsoe’s and Fathopes Energy’s Sustainable Aviation Fuel (SAF) project—using HydroFlex™ hydrotreating technology to process waste cooking oil—not only secured GITA subsidies but also became the first biofuel production facility in Southeast Asia certified under ISCC standards, thanks to compliance with the EU’s ReFuelEU criteria. Its annual processing capacity reaches 200,000 tons, achieving CO₂-equivalent emissions reductions of 500,000 tons per year. 3. Investment Tax Allowance (ITA): A Full Deduction Channel for Capital Expenditure Enterprises may apply for ITA deductions of up to 100% against statutory income generated from new business operations or expansion projects, within five years starting from the date of the first capital expenditure. This policy synergizes with BioNexus certification: certified enterprises enjoy ten consecutive years of statutory income tax exemption on non-intellectual-property income after their initial tax holiday period expires. For example, bio-based enterprises supported by the Agricultural Venture Fund (AGVF) can use the ITA policy to directly offset taxable income with capital expenditures—significantly lowering initial investment costs. II. Industry-Specific Incentives: End-to-End Support from R&D to Export 4. BioNexus Status Certification: The ‘Golden Passport’ for Life Sciences BioNexus certification serves as the core identity credential for Malaysian biotechnology enterprises. Beyond the aforementioned tax exemptions, certified enterprises also qualify for the Industrial Building Allowance (IBA)—an annual subsidy equal to 10% of qualifying building expenditures, payable for up to 10 years. Import duty and sales tax exemptions cover raw materials, components, and machinery, establishing a full ‘import–production–export’ tax-free corridor. For example, after obtaining BioNexus certification, a biopharmaceutical enterprise had its imported gene sequencers and bioreactors fully exempted from import duties—substantially reducing R&D costs. 5. R&D and Innovation Incentives: The Leverage Effect of Double Deduction The double-deduction policy for R&D expenditures directly encourages enterprises to increase innovation investment. According to Malaysia’s 2023 Budget, eligible R&D expenditures may be deducted from taxable income at 200% of the actual amount incurred.

BioNexus Launches Unified Website Covering Industrial Chemicals, Gene Screening, and Health Projects

1 day ago

BioNexus Gene Lab Corp launched a new website unifying data on its RNA screening, industrial chemicals, and healthcare investments. CEO Sam Tan noted the site helps stakeholders understand the company's diverse operations and technology relationships.

Stock Titan

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings

2026-04-14

BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)

2026-05-15

BioNexus Gene Lab Corp Q1 2026 Earnings: Revenue $22.84K, EPS ($0.23)